ExpansionLonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites 12.11.2024 / 07:00 CET/CEST The expansion of bioconjugation capabilities will provide additional ...

Swiss stocks tumbled on Friday, weighed down data showing a slowdown in growth, and uncertainty about Fed interest rate cuts ...

Find out more at www.lonza.com Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities ...

Lonza Group said it will expand manufacturing capacity at an existing facility in Visp, Switzerland, in response to growing demand for cancer drugs known as antibody-drug conjugates and similar ...

Lonza Group said it will expand manufacturing capacity at an existing facility in Visp, Switzerland, in response to growing demand for cancer drugs known as antibody-drug conjugates and similar ...

On Wednesday, Goldman Sachs initiated coverage on Lonza Group AG (LONN:SW) (OTC: LZAGY) shares, a major player in the pharmaceutical and biotech outsourcing sector, with a Buy ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class ...

High-throughput screening (HTS) enables the rapid testing of numerous compounds against biological targets. By automating and ...